Articles On Medadvisor (ASX:MDR)

ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7%  Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K...

ASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decline Ironbark Zinc jumps 75% on new leadership   The ASX kicked off November with a thud, sliding about 0.5%. This  follows a tough session o...

ASX health stocks fall 2.15% in past five days, while broader market down 1.42%  MedAdvisor drops 30% on latest quarterly result as MicroX and Mach 7 also fall Micro X reports a ‘ho-hum’ results, while AGMs so far remain rather uneventful ...

  ASX slips  amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine   The ASX slipped by 0.22% after being dragged by a flurry of company...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Industry leaders collaborate to bring innovative approaches to evolving pharmacy...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

The ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian stocks mostly declined amid ongoing economic weakness    After a sluggish start, the ASX ended Monday higher by 0.22% as September trading...

Clinuvel’s shares jump after reporting a $35.6 million profit for FY24 The company hits its eighth consecutive profitable year MedAdvisor turns a profit for the first time   A couple of health stocks announced their FY24 earnings this mor...

Nvidia’s stock dropped despite strong earnings and future guidance SuperMicro shares fell over 19pc due to a delay in filing annual report Telegram CEO Pavel Durov faces serious charges in France   The ASX is expected to fall when the mar...

A cooperative research centre believes there is an opportunity to transform Australia’s healthcare sector through digital innovations Alcidion helps health organisations harnesses the power of technology to empower digitally enabled care B...

ASX health stocks rise 0.8% past five days as broader market lifts 3.7%  Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24  CSL falls on FY24 results but Morgans still bullish on ASX’s largest h...

ASX health stocks fall 0.37% over past five days in line with broader markets  Cardiac company Imricor’s VISABL-AFL trial for US FDA starts in US LBT Innovations has secured a major deal with big pharma AstraZeneca Healthcare and life sci...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

It's been a decent start to both the month of July and the 2025 financial year for ASX shares so far. Since the end of FY24, the All Ordinaries Index (ASX: XAO) has risen by a tentative 0.25%. But let's talk about one ASX healthcare stock t...

ASX health stocks fall 0.19% in past five days as broader markets lift 0.79% Morgans says capital raises remain a theme for 2024 among healthcare stocks Pharmaceutical distributor EBOS increases stake in MedAdvisor to 9.8% Healthcare and...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Tesltra slumps, iron ore miners gain BHP faces a deadline today to decide on its bid for Anglo America Webjet reveals plans to split its travel divisions, boosting its share price today   The ASX 200 closed flattish on Wednesday, as big l...

MedAdvisor Solutions (ASX: MDR) is forecasting further strong growth over the next 12 months after achieving robust recent performances in sales and revenue. The Melbourne-headquartered patient engagement solution provider reported strong m...

MedAdvisor guides the market to maiden profit MedAdvisor (ASX:MDR) jumped +15% this morning after providing guidance for the full year ending this June. Based on the strong start to Q4 FY24 and anticipated activity levels over the remainder...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

If you're on the look at for some ASX dividend stocks to buy for your income portfolio, then you may want to check out the three listed below. Here's what you need to know about these income options: Coles Group Ltd (ASX: COL) Analysts at...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The S&P/ASX 200 Index (ASX: XJO) enjoyed another positive session today, as the recovery from last week's slump continues. A confident session saw the ASX 200 add a decent 0.4...

The ASX200 closed .4 of a per cent up with IT and Health Care the locomotives of a sluggish steam energy labouring under the weight of Energy and Industrials. IT and Health Care were up 1.73 and 1.22 per cent respectively whilst Energy a...

While the US economy is seen as a leading indicator for the world, the US Fed is unlikely to be the first major central bank to start cutting interest rates, says AMP deputy chief economist Diana Mousina. Mousina points out that the US...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is pushing higher again. At the time of writing, the benchmark index is up 0.4% to 7,681.2 points. Four ASX shares that are rising more than most today are listed below. Here's why...

The Wesfarmers Ltd (ASX: WES) share price is treading water today on fresh acquisition rumours. Shares in the diverse retailing conglomerate are down 0.4% to $65.33. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is up 0.4%. After a...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

MedAdvisor will pay £1 million (A$1.9 million) to UK pharmacy market app provider Charac Charac will see MedAdvisor pick up a 7.4 per cent shareholding MedAdvisor’s Rick Ratliff will become an NED on Charac’s board MedAdvisor wi...

So much for a small rise on the market today. Instead, the ASX200 closed down about three quarters (.76) per cent. Real estate stocks proved the biggest drag, down just over one and a quarter of a per cent, while IT was the only sector t...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Amplia reports positive data from pancreatic cancer trial Emyria was given endorsement by ethical committee for its TGA application MedAdvisor’s Q1 sales were up 27pc   Amplia reports promising data from pancreatic cancer trial Amplia The...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The ASX 200 benchmark falls 0.6% as we brace for news from The Fed Sector losses led by Resources, while Consumers make gains Small caps led by Alderan, and BNPL Sezzle returns   Local markets made it a hat trick of losses, with the re...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

ASX is set to rise for a third consecutive day Tech stocks in the US rallied overnight after a soft jobs market report Dividends rose in Q2 in Australia and around the world   The ASX is set to open higher for a third consecutive day afte...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...